Onasemnogene abeparvovec about 1 set,and 22 other contracts<br />

2026-11-03

Official in charge of disbursement of the procuring entity : Yuji Hiramatsu, The Obligating Officer Director, University of Tsukuba Hospital Classification of the products to be procured : Nature and quantity of the products to be purchased : A Onasemnogene abeparvove about set B Ravulizumab (Genetical Recombination) 300mg/3mL 1vial/case about 90 cases C Ravulizumab (Genetical Recombination) 1100mg/11mL 1vial/case about 20 cases D Crovalimab (Genetical Recombination) 340mg/2mL 1vial/case about 18 cases E Axicabtagene ciloleucel about 1 sets F Idecabtagene vicleucel about 1 sets G Pertuzumab (Genetical Recombination)・Trastuzumab (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) 10mL 1vial/case about 68 cases H Satralizumab (Genetical Recombination) 120mg/1mL 1syringe/case about 13 cases I Eculizumab (Genetical Recombination) 300mg/30mL 1vial/case about 23 cases J Sutimlimab (Genetical Recombination) 1100mg/22mL 1vial/case about 43 cases K Polatuzumab Vedotin (Genetical Recombination) 30mg 1vial/case about 40 cases L Garadacimab (Genetical Recombination) 200mg 1kit/case about 3 cases M Efgartigimod Alfa (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) 5.6mL 1vial/case about 15 cases N Tisagenlecleucel about sets O Mosunetuzumab (Genetical Recombination) 30mg/30mL 1vial/case about 3 cases P Glucarpidase (Genetical Recombination) 1000U 1vial/case about 1 cases Q Pertuzumab (Genetical Recombination)・Trastuzumab (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) 15mL 1vial/case about 6 cases R Risdiplam 5mg 7tablets/case about 6 cases Teduglutide (Genetical Recombination) 3.8mg 1vial/case about 33 cases T Polatuzumab Vedotin (Genetical Recombination) 140mg 1vial/case about 2 cases U Cetuximab Sarotalocan Sodium (Genetical Recombination) 250mg/50mL 1vial/case about 2 cases V Nusinersen Sodium 12mg/5mL 1vial/case about cases W Andexanet Alfa (Genetical Recombination) 200mg 1vial/case about 5 cases Delivery period : From April, 202 through 3 March, 202 Delivery place : The University of Tsukuba Hospital Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall : A not come under Article 4 and 4 of the Regulation concerning the Contract for University of Tsukuba Furthermore, minors, Person under Conservatorshi or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause, B have the Grade A, Grade B or Grade C qualification during fiscal 202 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency, C prove to have obtained either the first-class license or the third-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices, D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by The Obligating Officer, E meet the qualification requirements which The Obligating Officer Director may specify in accordance with Article 4 of the Regulation, F not be currently under a suspension of business order as instructed by The Obligating Officer. Time limit of tender : 1 : 0 1 March, 202 Contact point for the notice : Yuki Murasawa, Division of Accounting, Department of University Hospital Management, University of Tsukuba, 2-1- Amakubo Tsukuba-shi 305-857 Japan, TEL 029-853-354 ⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.

Japan

2026-03-26